natgillin/translations-raw huggingface dataset:
for the prevention of VTE in elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE, apixaban should be used with caution;
pri preprečevanju VTE pri načrtovani kirurški zamenjavi kolka ali kolena, preprečevanju možganske kapi ter sistemske embolije pri bolnikih z NVAF in preprečevanju ponovne GVT ter PE je treba apiksaban uporabljati previdno.
For the prevention of VTE, the adverse reactions reported by the investigator as at least possibly related to fondaparinux are presented within each frequency grouping (very common  1/10; common:
Neželeni učinki, o katerih so poročali raziskovalci pri preprečevanju VTE in za katere je možna vsaj majhna povezava s fondaparinuksom, so navedeni v skupinah glede na pogostnost (zelo pogosti
For the primary endpoint (per protocol population), there were 139 (49 Prevenar 13: 90 Placebo) first episodes of VT-CAP resulting in an efficacy of 45.56% (95.2% CI, 21.82-62.49; p=0.0006).
Za primarni opazovani dogodek (v populaciji po protokolu) je bilo 139 (49 Prevenar 13 : 90 placebo) prvih epizod VT-CAP, torej je učinkovitost znašala 45,56 % (95,2 % IZ; 21,82-62,49; p = 0,0006).
For the primary endpoint, stroke and SEE, no subgroups (i.e., age, weight, gender, renal function, ethnicity, etc.) were identified with a different risk ratio compared to warfarin.
Glede primarnega opazovanega dogodka, in sicer možganske kapi in sistemskih emboličnih dogodkov, ni bilo pri nobeni od podskupin (starost, telesna masa, spol, ledvično delovanje, etnična pripadnost itd) ugotovljeno drugačno razmerje tveganja v primerjavi z varfarinom.
For the primary endpoint, stroke and SEE, no subgroups (i.e., age, weight, gender, renal function, ethnicity, etc.) were identified with a different risk ratio compared to warfarin.
Glede primarnega opazovanega dogodka, in sicer možganske kapi in sistemskih emboličnih dogodkov, ni pri nobeni od podskupin (starost, telesna masa, spol, ledvično delovanje, etnična pripadnost itd) ugotovljeno drugačno razmerje tveganja v primerjavi z varfarinom.
For the primary endpoint, which was incidence of cataract development or progression at 12 months (defined as an increase of ≥ 0.3 in the LOCS III score), a greater proportion of subjects experienced cataract development in the palifermin group compared with the placebo group (28.6 % in the placebo group vs 48.1% in the palifermin group).
Kar se tiče primarnega cilja raziskave, ki je bil pojavnost razvoja katarakte ali njeno napredovanje po 12 mesecih (opredeljeno kot povečanje ocene po lestvici LOCS III za ≥ 0,3), je v skupini, zdravljeni s paliferminom, prišlo do razvoja katarakte pri večjem deležu preiskovancev kot v kontrolni skupini (28,6 % v kontrolni skupini v primerjavi z 48,1 % v skupini, zdravljeni s paliferminom).
For the purpose of ambulatory use, Aranesp may be removed from storage once for a maximum single period of seven days at room temperature (up to 25C).
Za ambulantno rabo je zdravilo Aranesp mogoče vzeti iz prostora za shranjevanje enkrat za največ eno sedemdnevno obdobje pri sobni temperaturi (do 25ºC).
For the purpose of ambulatory use, Cyanokit may be exposed during short periods to the temperature variations of usual transport (15 days submitted to temperatures ranging from 5 to 40°C) transport in the desert (4 days submitted to temperatures ranging from 5 to 60°C) and freezing/defrosting cycles (15 days submitted to temperatures ranging from -20 to 40°C).
Pri ambulantni uporabi se lahko zdravilo Cyanokit za kratek čas izpostavi naslednjim temperaturnim območjem: običajni prevoz (15 dni izpostavljenosti temperaturam od 5 °C do 40 °C), prevoz v puščavi (4 dni izpostavljenosti temperaturam od 5 °C do 60 °C) in cikli zamrzovanja/odmrzovanja (15 dni izpostavljenosti temperaturam od –20 °C do 40 °C)
For the purpose of ambulatory use, Cyanokit may be exposed during short periods to the temperature variations of usual transport (15 days submitted to temperatures ranging from 5°C to 40°C), transport in the desert (4 days submitted to temperatures ranging from 5°C to 60°C) and freezing/defrosting cycles (15 days submitted to temperatures ranging from -20°C to 40°C).
Pri ambulantni uporabi se lahko zdravilo Cyanokit krajši čas izpostavlja temperaturnim razlikam, ki nastanejo med običajnim transportom (15 dni temperaturam od 5 °C do 40 °C), med transportom v puščavi (4 dni temperaturam od 5 °C do 60 °C) in ciklom zamrzovanja/odmrzovanja (15 dni temperaturam od –20 °C do 40 °C).
For the purpose of ambulatory use, Nespo may be removed from storage once for a maximum single period of seven days at room temperature (up to 25C).
Za ambulantno rabo je Nespo mogoče vzeti iz prostora za shranjevanje enkrat za največ eno sedemdnevno obdobje pri sobni temperaturi (do 25ºC).
For the purpose of ambulatory use, the medicinal product may be taken out of the refrigerator, without being replaced, for a maximum period of 3 days at a temperature not above 25 °C. If the medicinal product has not been used at the end of this period, it should be disposed of.
Pri ambulantnem zdravljenju se lahko zdravilo vzame iz hladilnika in je zunaj njega največ 3 dni pri temperaturi do 25 °C. Če zdravila do konca tega obdobja ne porabite, ga je treba zavreči.
For the purpose of ambulatory use, the patient may remove the product from the refrigerator and store it at a temperature not above 25 °C for a single period of up to 7 days without exceeding the expiry date.
Za ambulantno uporabo lahko bolnik zdravilo vzame iz hladilnika in ga shranjuje pri temperaturi, nižji od 25 C, do sedem dni.
For the purpose of ambulatory use, the patient may remove the product from the refrigerator and store it at room temperature (not above 25°C) for one single period of up to 3 days.
Med ambulantno uporabo lahko bolnik zdravilo vzame iz hladilnika in ga nato hrani pri sobni temperaturi (do 25 ºC), vendar največ 3 dni.
For the purpose of ambulatory use, the patient may remove the unreconstituted product from the refrigerator and store it at room temperature (not above 25°C) for one single period of up to 5 days.
Med ambulantno uporabo lahko bolnik prašek vzame iz hladilnika in ga nato hrani pri sobni temperaturi (do 25 ºC), vendar največ 5 dni.
For the purpose of this table, a cut off of 5 % was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed and cisplatin.
Za namen te preglednice smo uporabili »cut off« 5 % za vključitev vseh dogodkov, kjer je poročevalec upošteval možno povezavo s pemetreksedom.
For the purpose of this table, a cut off of 5% was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed and cisplatin.
Za namen te preglednice smo uporabili »cut off« 5 % za vključitev vseh dogodkov, kjer je poročevalec upošteval možno povezavo s pemetreksedom.
For the purpose of this table, a cut off of 5% was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed.
Za namen te preglednice smo uporabili »cut off« 5 % za vključitev vseh dogodkov, kjer je poročevalec upošteval možno povezavo s pemetreksedom.
For the purpose of this table, a cut-off of 5 % was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed and cisplatin.
Za namen te preglednice smo uporabili »cut off« 5 % za vključitev vseh dogodkov, kjer je poročevalec upošteval možno povezavo pemetrekseda in cisplatina.
For the purpose of this table, a cut-off of 5 % was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed and cisplatin.
Za namen te preglednice smo uporabili »cut off« 5 % za vključitev vseh dogodkov, kjer je poročevalec upošteval možno povezavo s pemetreksedom.
For the purpose of this table, a cut-off of 5% was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed and cisplatin.
Za namen te preglednice smo uporabili »cut off« 5 % za vključitev vseh dogodkov, kjer je poročevalec upošteval možno povezavo s pemetreksedom.
For the purpose of this table, a cut-off of 5% was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed and cisplatin.
Za namen te preglednice smo uporabili »cut off« 5% za vključitev vseh dogodkov, kjer je poročevalec upošteval možno povezavo s pemetreksedom in cisplatinom.
For the purpose of this table, a cut-off of 5% was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed and cisplatin.
Za namen te preglednice so uporabili »cut off« 5 % za vključitev vseh dogodkov, kjer je poročevalec upošteval možno povezavo s pemetreksedom.
For the purpose of this table, a cutoff of 5 % was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed.
Za namen te preglednice smo uporabili »cut off« 5 % za vključitev vseh dogodkov, kjer je poročevalec upošteval možno povezavo s pemetreksedom.
For the purpose of this table, a cutoff of 5% was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed.
Za namen te preglednice smo uporabili »cut off« 5 % za vključitev vseh dogodkov, kjer je poročevalec upošteval možno povezavo s pemetreksedom.
For the purpose of this table, a cutoff of 5% was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed.
Za namen te preglednice smo uporabili »cut off« 5% za vključitev vseh dogodkov, kjer je poročevalec upošteval možno povezavo s pemetreksedom.
For the purpose of this table, a cutoff of 5% was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed.
Za namen te preglednice so uporabili »cut off« 5 % za vključitev vseh dogodkov, kjer je poročevalec upošteval možno povezavo s pemetreksedom.
For the reduction in the incidence of ketosis in the peri-parturient dairy cow/heifer which is expected to develop ketosis.
Za zmanjšanje pojavnosti ketoze pri kravah molznicah in telicah v obporodnem obdobju, pri katerih se pričakuje razvoj ketoze.
For the reduction of moderate pain and inflammation associated with orthopaedic surgery in cats.
Za zmanjševanje zmerne bolečine in vnetja v povezavi z ortopedskimi operativnimi posegi pri mačkah.
For the relief of pain and inflammation associated with osteoarthritis in dogs.
Za lajšanje bolečin in blaženje vnetja povezanih z osteoartritisom pri psih.
For the relief of post-operative pain and inflammation associated with soft-tissue, orthopaedic and dental surgery in dogs.
Za lajšanje post-operativne bolečine in blaženje vnetja, povezanih z operativnimi posegi na mehkih tkivih,ortopedskimi operativnimi posegi in zobni kirurgiji pri psih.
For the relief of post-operative pain associated with minor soft tissue such as castration.
Za lajšanje postoperativnih bolečin, povezanih z manjšimi operacijami mehkega tikva, na primer s kastracijo.
For the relief of post-operative pain associated with minor soft tissue surgery such as castration.
Za blažitev bolečine po operaciji, povezani z manjšimi posegi na mehkem tkivu, kot je npr. kastracija.
For the remainder of the day after injection, patients should be advised to be vigilant for signs and symptoms of overdose secondary to post injection adverse reactions, be able to obtain assistance if needed and should not drive or operate machinery (see section 4.7).
Za preostanek dneva po injiciranju je potrebno bolnike opozoriti, naj bodo pozorni na znake in simptome prevelikega odmerjanja, ki nastopijo sekundarno po neželenih reakcijah po injiciranju, da bodo lahko po potrebi poiskali pomoč, ter naj ne vozijo ali upravljajo s stroji (glejte poglavje 4.7).
For the removal of an epidural catheter and based on the general PK characteristics at least 2x half- life, i.e. at least 18 hours in young patients and 26 hours in elderly patients should elapse after the last administration of rivaroxaban (see section 5.2).
Za odstranitev epiduralnega katetra in glede na splošne farmakokinetične lastnosti mora po zadnji uporabi rivaroksabana preteči vsaj 2-kratni razpolovni čas t.j. najmanj 18 ur pri mlajših bolnikih in 26 ur pri starejših bolnikih (glejte poglavj 5.2).
For the removal of an epidural catheter and based on the general PK characteristics at least 2x half- life, i.e. at least 18 hours in young patients and 26 hours in elderly patients should elapse after the last administration of rivaroxaban (see section 5.2).
Za odstranitev epiduralnega katetra in glede na splošne farmakokinetične lastnosti mora po zadnji uporabi rivaroksabana preteči vsaj 2-kratni razpolovni čas t.j. najmanj 18 ur pri mlajših bolnikih in 26 ur pri starejših bolnikih (glejte poglavje 5.2).
For the resistance analysis, a broader definition of virologic failure was used than in the primary efficacy analysis.
Za analizo rezistence je bila uporabljena obsežnejša definicija virološkega neuspeha zdravljenja kot pri primarni analizi učinkovitosti.
For the safety and health of you and others, needles and used syringes must never be re-used.
Iz varnostnih razlogov in za lastno zaščito ter zaščito zdravja drugih ljudi nikoli ponovno ne uporabljajte igel in uporabljenih brizg.
For the same reason, concomitant administration of both a potent CYP3A4 inhibitor (such as ketoconazole, itraconazole or ritonavir) and a CYP2C9 inhibitor (such as voriconazole) with STAYVEER is not recommended.
Iz istega razloga odsvetujemo sočasno uporabo zdravila STAYVEER tako z močnim zaviralcem CYP3A4 (denimo, ketokonazolom, itrakonazolom ali ritonavirjem) in tudi zaviralcem CYP2C9 (denimo, vorikonazolom).
For the same reason, concomitant administration of both a potent CYP3A4 inhibitor (such as ketoconazole, itraconazole or ritonavir) and a CYP2C9 inhibitor (such as voriconazole) with Tracleer is not recommended.
Iz istega razloga odsvetujemo sočasno uporabo zdravila Tracleer tako z močnim zaviralcem CYP3A4 (denimo, ketokonazolom, itrakonazolom ali ritonavirjem) in tudi zaviralcem CYP2C9 (denimo, vorikonazolom).
For the sequence IV→SC (SC vial and SC formulation in administration system cohorts combined), adverse event rates (all grades) were described pre- switching (Cycles 1-4) and post-switching (Cycles 5-8) as 53.8% vs.
Za prehod iv. → s.c. (skupaj za obe s.c. obliki: v viali in aplikacijskem sistemu) je bila pogostnost neželenih učinkov (vseh stopenj) pred prehodom (1. do 4. cikel) 53,8 % in po prehodu (5. do 8. cikel) 56,4 %.
For the shelf life and the precautions for storage after reconstitution, see section 5 of the leaflet.
Za rok uporabnosti in previdnostne ukrepe pri shranjevanju rekonstituiranega zdravila glejte poglavje 5 v navodilu za uporabo zdravila.
For the shelf-life and the precaution for storage after reconstitution, see section 6.3.
Za rok uporabnosti in previdnostne ukrepe pri shranjevanju rekonstituiranega zdravila glejte poglavje 6.3.
For the single-dose nasal spray all unused devices or empty containers should be returned systematically according to the local regulation.
Za enoodmerno pršilo za nos - vsa neuporabljena pršila ali prazne vsebnike je treba sistematično vračati v skladu z lokalnimi predpisi.
For the standard dose of 45 mg once daily, a 45 mg film-coated tablet is available.
Za standardni odmerek 45 mg enkrat na dan je na voljo 45 mg filmsko obložena tableta.
For the storage condition after reconstitution of the product see section 6.3.
Za pogoje shranjevanja po rekonstituciji zdravila glejte poglavje 6.3.
For the storage of unused broken tablets, see HOW TO STORE SIKLOS.
Za shranjevanje neporabljenih prelomljenih tablet glejte Shranjevanje zdravila Siklos
For the subgroup of patients who received Quinsair throughout the Core and Extension Phases (i.e.
Za podskupino bolnikov, ki so prejemali zdravilo Quinsair ves čas osrednje faze in faze podaljška (tj.
For the subjects who were dose reduced to 30 mg (predominantly low body weight or renal function) 15 (2.1%) edoxaban and 22 (3.1%) of warfarin subjects had a recurrent VTE [HR (95% CI): 0.69 (0.36, 1.34)].
Od preiskovancev, ki jim je bil odmerek zmanjšan na 30 mg (prevladujoča razloga sta bila majhna telesna masa ali funkcija ledvic), je imelo 15 (2,1 %) preiskovancev z edoksabanom in 22 (3,1 %) preiskovancev z varfarinom recidivne VTE [HR (95 % CI): 0,69 (0,36, 1,34)].
For the surviving juvenile rats, no effects on behavioural or reproductive performance were observed.
Pri preživelih podganjih mladičih niso opažali nobenega vpliva na vedenje in sposobnost razmnoževanja.
For the three additional polysaccharides (1, 5, 7F), Synflorix was effective in triggering the production of antibodies.
Cepivo Synflorix je bilo učinkovito pri sprožitvi tvorbe protiteles proti trem dodatnim polisaharidom (1, 5, 7F).
For the time being there is no well established definition of a high risk patient, although a more conservative approach is to accept at least nine T2 hyperintense lesions on the initial scan and at least one new T2 or one new Gd-enhancing lesion on a follow-up scan taken at least 1 month after the initial scan.
Do danes dobro utemeljene opredelitve bolnika z velikim tveganjem še ni, vendar je bolj sprejemljiv konzervativen pristop, to pomeni vsaj 9 hiperintenzivnih lezij T2 v prvi preiskavi in vsaj ena nova T2 ali ena nova lezija po ojačanju z Gd v naslednji preiskavi, ki je izvedena vsaj 1 mesec po prvi preiskavi.
For the time period of observation of historical controls: 1/16 patients displayed apparent catch-up height-gain, 12/16 patients did not display apparent catch-up height-gain and data were inconclusive in 3/16 patients.
Za obdobje opazovanja zgodovinskih kontrolnih podatkov: pri 1 od 16 bolnikov se je pokazalo navidezno dohitevanje v pridobivanju višine, pri 12 od 16 bolnikov se ni pokazalo navidezno dohitevanje v pridobivanju višine in za 3 od 16 bolnikov podatki niso dovoljevali sklepanja.
For the treatment and control of Ascaris suum and Oesophagostomum spp. this dose has to be administered on 2 consecutive days.
Za zdravljenje in nadzor Ascaris suum in Oesophagostomum spp. je treba dati ta odmerek dva zaporedna dneva.
For the treatment and prevention of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni sensitive to tildipirosin.
Za zdravljenje in preprečevanje respiratorne bolezni goveda (BRD), povezane z Mannheimia haemolytica, Pasteurella multocida in Histophilus somni, ki so občutljivi za tildipirozin.
For the treatment and prevention of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni sensitive to tildipirosin.
Za zdravljenje in preprečevanje respiratorne bolezni goveda (BRD), povzročene z Mannheimia haemolytica, Pasteurella multocida in Histophilus somni, ki so občutljivi za tildipirozin.
For the treatment and prevention of flea (Ctenocephalides felis) infestations in dogs when the concurrent prevention of heartworm disease (L3, L4 Dirofilaria immitis) and/or treatment of gastrointestinal nematode infections caused by hookworm (L4, immature adult (L5) and adult Ancylostoma caninum), roundworms (immature adult L5, and adult Toxocara canis and adult Toxascaris leonina) and whipworm (adult Trichuris vulpis) is indicated.
Za zdravljenje in preprečevanje infestacij z bolhami (Ctenocephalides felis) pri psih, kadar je indicirano sočasno preprečevanje dirofilarioze (L3, L4 Dirofilaria immitis) in/ali sočasno zdravljenje okužb z želodčno-črevesnimi nematodi ki jih povzročajo kavljasti črvi (L4, nezrele odrasle oblike (L5) in odrasle oblike Ancylostoma caninum ), valjasti črvi (nezrele odrasle oblike L5 in odrasle oblike Toxocara canis in odrasle oblike Toxascaris leonina) in bičeglavci (odrasle oblike Trichuris vulpis).
for the treatment and prevention of flea infestations in cats, ferrets and dogs
za zdravljenje in preprečevanje infestacije z bolhami pri mačkah, belih dihurjih in psih;
For the treatment and prevention of flea infestations.
Zdravljenje in preprečevanje infestacij z bolhami.
For the treatment and prevention of fungal infections, the recommended dose of Noxafil tablets or Noxafil solution for infusion is 300 mg twice a day on the first day followed by 300 mg once a day thereafter; the duration of treatment depends on the severity of the disease and the patient’s response.
Pri zdravljenju in preprečevanju glivičnih okužb znaša priporočeni odmerek tablet ali raztopine za infundiranje zdravila Noxafil prvi dan 300 mg dvakrat na dan, zatem pa se nadaljuje z odmerkom 300 mg enkrat na dan, pri čemer je trajanje zdravljenja odvisno od resnosti bolezni in bolnikovega odziva.
For the treatment and prevention of infestations by fleas (Ctenocephalides canis and C. felis) and ticks (Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus, Dermacentor reticulates and Dermacentor variabilis), and treatment of demodicosis (caused by Demodex spp.) and lice (Trichodectes canis) in dogs.
Zdravljenje in preprečevanje bolhavosti (Ctenocephalides canis in C. felis) in klopavosti (Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus, Dermacentor reticulatus in Dermacentor variabilis) ter zdravljenje demodikoze (ki jo povzroča Demodex spp.) in ušivosti (Trichodectes canis) pri psih.
For the treatment and prevention of infestations by fleas (Ctenocephalides canis and C. felis), and ticks (Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus, Dermacentor reticulatus and Dermacentor variabilis), and treatment of demodicosis (caused by Demodex spp.) and lice (Trichodectes canis) in dogs.
Zdravljenje in preprečevanje bolhavosti (Ctenocephalides canis in C. felis) in klopavosti (Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus, Dermacentor reticulatus in Dermacentor variabilis) ter zdravljenje demodikoze (ki jo povzroča Demodex spp.) in ušivosti (Trichodectes canis) pri psih.
For the treatment and prevention of infestations by fleas.
Za zdravljenje in preprečevanje bolhavosti.
For the treatment and prevention of nausea induced by chemotherapy.
Za zdravljenje in preprečevanje slabosti, povzročene zaradi kemoterapije.
For the treatment benign prostatic hyperplasia
Za zdravljenje benigne hiperplazije prostate
For the treatment of
Za zdravljenje motenj
For the treatment of acromegaly, Signifor was investigated in two main studies.
Za zdravljenje akromegalije so zdravilo Signifor proučevali v dveh glavnih študijah.
For the treatment of acute otitis externa, and acute exacerbation of recurrent otitis externa associated with Staphylococcus pseudintermedius and Malassezia pachydermatis.
Zdravljenje akutnega vnetja zunanjega sluhovoda ter akutnega poslabšanja ponavljajočega se vnetja zunanjega sluhovoda, povezanega z bakterijo Staphylococcus pseudintermedius in glivico Malassezia pachydermatis.
For the treatment of acute pain and inflammation associated with musculo-skeletal disorders in cats.
Za zdravljenje akutne bolečine in vnetja v povezavi z mišičnoskeletnimi obolenji pri mačkah.
For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
Za zdravljenje odraslih in otrok z diabetesom mellitusom, ki potrebujejo insulin za vzdrževanje normalne homeostaze glukoze.
For the treatment of adults with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
Za zdravljenje odraslih z diabetesom mellitusom, ki potrebujejo insulin za vzdrževanje normalne homeostaze glukoze.
For the treatment of advanced breast cancer, docetaxel could be administered either alone or in combination with doxorubicin, or trastuzumab, or capecitabine.
Za zdravljenje napredovalega raka dojke se lahko docetaksel uporablja sam ali v kombinaciji z doksorubicinom ali trastuzumabom ali kapecitabinom.
For the treatment of advanced breast cancer, DOCETAXEL KABI could be administered either alone or in combination with doxorubicin, or trastuzumab, or capecitabine.
Za zdravljenje napredovalega raka dojke se lahko zdravilo DOCETAKSEL KABI uporablja sam ali v kombinaciji z doksorubicinom ali trastuzumabom ali kapecitabinom.